$50.33 Million in Sales Expected for Repligen Co. (RGEN) This Quarter

Share on StockTwits

Wall Street analysts expect that Repligen Co. (NASDAQ:RGEN) will announce $50.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Repligen’s earnings. The highest sales estimate is $50.62 million and the lowest is $49.93 million. Repligen reported sales of $41.61 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 21%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 28th.

On average, analysts expect that Repligen will report full-year sales of $192.43 million for the current fiscal year, with estimates ranging from $192.02 million to $192.71 million. For the next financial year, analysts forecast that the business will post sales of $219.06 million, with estimates ranging from $215.00 million to $223.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Repligen.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.02. The business had revenue of $49.53 million for the quarter, compared to the consensus estimate of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The business’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.15 earnings per share.

Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Wednesday. William Blair reiterated an “outperform” rating on shares of Repligen in a research note on Friday, November 2nd. HC Wainwright reiterated a “hold” rating and issued a $60.00 price objective on shares of Repligen in a research note on Monday. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. Finally, ValuEngine upgraded shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 23rd. Three analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $59.33.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,366 shares of Repligen stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $51.44, for a total transaction of $121,707.04. Following the completion of the transaction, the director now owns 4,988 shares in the company, valued at $256,582.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 1,763 shares of Repligen stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $65.75, for a total transaction of $115,917.25. Following the transaction, the director now owns 3,225 shares of the company’s stock, valued at approximately $212,043.75. The disclosure for this sale can be found here. Insiders sold 52,735 shares of company stock valued at $2,950,017 in the last quarter. Company insiders own 1.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Meadow Creek Investment Management LLC raised its position in shares of Repligen by 21.7% in the second quarter. Meadow Creek Investment Management LLC now owns 7,840 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 1,400 shares during the last quarter. Legal & General Group Plc grew its holdings in Repligen by 2.0% in the first quarter. Legal & General Group Plc now owns 77,094 shares of the biotechnology company’s stock valued at $2,771,000 after purchasing an additional 1,527 shares during the period. Brown Advisory Inc. grew its holdings in Repligen by 24.0% in the second quarter. Brown Advisory Inc. now owns 8,640 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 1,673 shares during the period. Arizona State Retirement System grew its holdings in Repligen by 3.3% in the third quarter. Arizona State Retirement System now owns 56,556 shares of the biotechnology company’s stock valued at $3,137,000 after purchasing an additional 1,818 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in Repligen by 30.8% in the second quarter. Envestnet Asset Management Inc. now owns 8,021 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 1,891 shares during the period. Institutional investors own 93.08% of the company’s stock.

Shares of NASDAQ:RGEN traded up $1.85 during midday trading on Friday, hitting $69.76. The stock had a trading volume of 39,341 shares, compared to its average volume of 523,591. The company has a market cap of $2.90 billion, a price-to-earnings ratio of 101.19, a PEG ratio of 5.22 and a beta of 0.74. Repligen has a 1 year low of $29.56 and a 1 year high of $68.50.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: What are defining characteristics of a correction?

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply